Ultragenyx Pharmaceutical Inc. financial data

Symbol
RARE on Nasdaq
Location
Novato, CA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 18 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 230% % -17%
Quick Ratio 15% % 4.9%
Debt-to-equity 2264% % 457%
Return On Equity -1024% % -428%
Return On Assets -43% % -13%
Operating Margin -79% % 17%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 96,629,788 shares 4.5%
Common Stock, Shares, Outstanding 96,600,000 shares 4.4%
Entity Public Float $3,400,000,000 USD -8.1%
Common Stock, Value, Issued $0 USD
Weighted Average Number of Shares Outstanding, Basic 98,600,000 shares 9%
Weighted Average Number of Shares Outstanding, Diluted 98,600,000 shares 9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $673,000,000 USD 20%
Research and Development Expense $750,000,000 USD 7.4%
Operating Income (Loss) $535,000,000 USD 0.19%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $571,000,000 USD -0.7%
Income Tax Expense (Benefit) $4,000,000 USD 100%
Net Income (Loss) Attributable to Parent $575,000,000 USD -1.1%
Earnings Per Share, Basic -5.83 USD/shares 7.3%
Earnings Per Share, Diluted -5.83 USD/shares 7.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $421,000,000 USD 142%
Accounts Receivable, after Allowance for Credit Loss, Current $158,000,000 USD 30%
Inventory, Net $52,000,000 USD 16%
Other Assets, Current $41,365,000 USD
Assets, Current $951,000,000 USD 16%
Property, Plant and Equipment, Net $244,000,000 USD -8.3%
Operating Lease, Right-of-Use Asset $23,000,000 USD -12%
Intangible Assets, Net (Excluding Goodwill) $176,000,000 USD -1.1%
Goodwill $44,000,000 USD 0%
Other Assets, Noncurrent $60,000,000 USD -4.8%
Assets $1,532,000,000 USD 1.9%
Accounts Payable, Current $31,000,000 USD -21%
Employee-related Liabilities, Current $89,000,000 USD -5.3%
Accrued Liabilities, Current $265,000,000 USD 10%
Liabilities, Current $384,000,000 USD 12%
Deferred Income Tax Liabilities, Net $30,000,000 USD 0%
Operating Lease, Liability, Noncurrent $24,000,000 USD -20%
Other Liabilities, Noncurrent $20,000,000 USD 18%
Liabilities $1,605,000,000 USD 29%
Accumulated Other Comprehensive Income (Loss), Net of Tax $1,000,000 USD
Retained Earnings (Accumulated Deficit) $4,532,000,000 USD -15%
Stockholders' Equity Attributable to Parent $80,000,000 USD -131%
Liabilities and Equity $1,532,000,000 USD 1.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $166,475,000 USD 13%
Net Cash Provided by (Used in) Financing Activities $157,000,000 USD
Net Cash Provided by (Used in) Investing Activities $119,890,000 USD 27%
Common Stock, Shares Authorized 250,000,000 shares 0%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $44,980,000 USD 54%
Deferred Tax Assets, Valuation Allowance $1,355,000,000 USD 12%
Deferred Tax Assets, Gross $1,361,000,000 USD 12%
Operating Lease, Liability $36,000,000 USD -11%
Payments to Acquire Property, Plant, and Equipment $1,324,000 USD -59%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $573,000,000 USD -0.35%
Lessee, Operating Lease, Liability, to be Paid $43,000,000 USD -13%
Property, Plant and Equipment, Gross $380,000,000 USD 0.53%
Operating Lease, Liability, Current $12,000,000 USD 20%
Lessee, Operating Lease, Liability, to be Paid, Year Two $10,000,000 USD -28%
Lessee, Operating Lease, Liability, to be Paid, Year One $15,000,000 USD 8.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure -0.99%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $7,000,000 USD -24%
Lessee, Operating Lease, Liability, to be Paid, Year Three $8,000,000 USD -11%
Deferred Tax Assets, Operating Loss Carryforwards $511,000,000 USD 65%
Preferred Stock, Shares Authorized 25,000,000 shares 0%
Unrecognized Tax Benefits $111,000,000 USD 14%
Lessee, Operating Lease, Liability, to be Paid, Year Four $7,000,000 USD 4.3%
Additional Paid in Capital $4,451,000,000 USD 5.6%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $8,990,000 USD 1.6%
Deferred Tax Assets, Net of Valuation Allowance $6,000,000 USD -14%
Share-based Payment Arrangement, Expense $153,000,000 USD -3.2%
Preferred Stock, Par or Stated Value Per Share 0.001 USD/shares 0%